TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12101195
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of neoadjuvant hormonal treatment (NHT)
Study: 10438352
Drug: Indinavir, zidovudine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir, zidovudine, and lamivudine (triple therapy)
Study: 2370328
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate cream applied for 0.5 hours
Study: 2370328
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate cream applied for 1.0 hours
Study: 2370328
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate cream applied for 1.5 hours
Study: 2370328
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate cream applied for 16.0 hours
Study: 2370328
Drug: 0.05% fluocinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% fluocinonide cream applied for 16 hours
Study: 29172680
Drug: DR/ER-MPH (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR/ER-MPH (40-80 mg/day)
Study: 19956761
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g)
Study: 21946903
Drug: Survivors using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survivors using hot flash treatments
Study: 14767813
Drug: Ganciclovir implant
Normalized name: ganciclovir Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir implant plus oral placebo
Study: 9431375
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir alone
Study: 10194235
Drug: Ganciclovir implant
Normalized name: ganciclovir Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir implant plus oral ganciclovir (4.5 g daily)
Study: 10194235
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir or intravenous ganciclovir
Study: 7582042
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment studies
Study: 2253196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (1 mg/m2 daily)
Study: 2253196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (3 mg/m2 daily)
Study: 2253196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (8 mg/m2 daily)
Study: 2253196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rhIL-2 (1 x 10(6) units/m2 i.v. over 6 h on days 1-5 and 8-12) and R24 (12 mg/m2 daily)
Study: 2253196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rhIL-2 and R24
Study: 7114512
Drug: Nicergoline (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (0.3 mg/kg bolus, 0.8 mg/kg/h maintenance)
Study: 27768397
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) supplementation (0.3 g・kg‐1・d‐1 for 5 days followed by 0.1 g・kg‐1・d‐1 for 23 days; n = 9)
Study: 26375599
Drug: Methylene blue-mediated
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue-mediated photodynamic inactivation followed by low-laser therapy
Study: 8290882
Drug: Miconazole gel
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole gel
Study: 7970483
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg/day) alone
Study: 7970483
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg/day) + MPA (5.0 mg/day continuously)
Study: 7970483
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg/day) + MPA (5.0 mg/day for last 14 days of each cycle)
Study: 7970483
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg/day) + MPA (10.0 mg/day for last 14 days of each cycle)
Study: 1105487
Drug: prazosin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin plus one or more other antihypertensive drugs
Study: 28431564
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 8% patch
Study: 14693607
Drug: Rofecoxib oral
Normalized name: rofecoxib Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib oral suspension 25 mg (Group B)
Study: 12491077
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (JCOG 8801 study)
Study: 2223157
Drug: Bestatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin treatment in adenocarcinoma
Study: 349961
Drug: Proteinase inhibiting
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proteinase inhibiting agents and glucagon
Study: 28247635
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy only
Study: 21334033
Drug: Oral beta-blockers
Normalized name: beta carotene Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta-blockers
Study: 14994390
Drug: Etodolac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (300 or 1000 mg daily)
Study: 7648827
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no supplementary insulin)
Study: 7648827
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (1.8U over 15 min, extended over 30 min)
Study: 30442551
Drug: Midazolam 15mg
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 15mg (oral)
Study: 20178033
Drug: Citalopram (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (selective serotonin reuptake inhibitor), duration: 12 weeks
Study: 11907350
Drug: Currently available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Currently available IBD therapies and those used in clinical trials for ulcerative colitis.
Study: 8006126
Drug: Artificial cycle
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial cycle (Goserelin 3.6 mg s.c. followed by hormone replacement therapy)
Study: 22647413
Drug: Amlodipine/valsartan 5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 5/160 mg SPC
Study: 24423017
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (LAI)
Study: 18572868
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of medication with local hyperthermia (CRS-2280E system, anal administration of 1 Qianliean suppository, oral doxazosin 4 mg before bedtime for 2 weeks)
Study: 24228532
Drug: Xuezhikang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang capsule
Study: 17933486
Drug: Buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone treatment
Study: 8853530
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) as consolidation therapy
Study: 2186651
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg intramuscularly
Study: 2186651
Drug: nefopam 20
Normalized name: nefopam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: nefopam 20 mg intramuscularly
Study: 2186651
Drug: oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral paracetamol as required
Study: 252699
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ten units of regular insulin (U.S.P.) twice daily
Study: 27734550
Drug: Percutaneous radiofrequency
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous radiofrequency treatment applied to the ramus communicans
Study: 27734550
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure (same procedure except radiofrequency treatment)
Study: 16990660
Drug: Lowest birth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest birth weight (<2500 g)
Study: 15589067
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (10 mg sibutramine/d + 3 x 120 mg orlistat/d, n = 20)
Study: 23885610
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy alone (group B)
Study: 23885610
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with rehabilitation therapy (group A)
Study: 16740370
Drug: Baclofen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (20 mg tid)
Study: 16740370
Drug: Gabapentin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (800 mg tid)
Study: 29020373
Drug: Artemether-Lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine (AL) - total target dose: 12 mg/kg for artemether and 60 mg/kg for lumefantrine
Study: 7863813
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (3 million IU/day for 6 days/week)
Study: 7863813
Drug: Epirubicin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (25 mg/m2 i.v. weekly)
Study: 2488472
Drug: Glucagon (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (0.5 mg i.v. bolus followed by 1.5 mg infused over 90 minutes)
Study: 23595161
Drug: CALM-BP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALM-BP treatment
Study: 18652319
Drug: Routine comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine comprehensive therapy and moxibustion at Zusanli (ST 36), Guanyuan (CV 4), Sanyinjiao (SP 6)
Study: 18652319
Drug: Routine comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine comprehensive therapy (including hemodialysis and medication)
Study: 16950175
Drug: Niacin treatment
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin treatment for 3 months
Study: 10766318
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with amoxicillin, clarithromycin, pantoprazole
Study: 10766318
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with tinidazole, clarithromycin, ranitidine bismuth citrate
Study: 10766318
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with tinidazole, clarithromycin, pantoprazole
Study: 10099862
Drug: Lamotrigine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (100 mg/day)
Study: 8823232
Drug: Lamotrigine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (150 mg/day)
Study: 8823232
Drug: Valproate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (500 mg Depakote twice a day)
Study: 30206423
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy (RT) using the Armeo Power
Study: 22409590
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg S-equol/day
Study: 22409590
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg S-equol/day
Study: 22409590
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg S-equol/day
Study: 2179067
Drug: Acyclovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (400 mg bid)
Study: 26519710
Drug: 20% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% human albumin (5 mL/kg)
Study: 26519710
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (5 mL/kg)
Study: 10699609
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (10-hertz square waves of 1-ms pulse duration, vaginal electrode for women, anal or surface electrode for men) for 15 minutes twice daily for 4 weeks
Study: 27404026
Drug: CE/BZA 0.45/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/BZA 0.45/20 mg
Study: 27404026
Drug: CE/BZA 0.625/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/BZA 0.625/20 mg
Study: 20537851
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine administered every 30 minutes until the second hour, then every 4 hours for 48 hours
Study: 20537851
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia with a mixture of 0.125% bupivacaine and 0.115% fentanyl continuously infused at 7 ml/h for 48 hours
Study: 18504089
Drug: Analgesic Imagery
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic Imagery
Study: 15503293
Drug: 6-thioguanine (TG)
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-thioguanine (TG) at a targeted dose of 50 mg/m²/day during maintenance therapy
Study: 22514211
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3 g/day for 4 weeks)
Study: 22514211
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (3 g/day for 4 weeks)
Study: 19460770
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 microg/kg/day) injection for 3 days after PCI in the AMI-G-CSF group.
Study: 19460770
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G-CSF treatment) in the OMI-control group.
Study: 19460770
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G-CSF treatment) in the healthy-control group.
Study: 17526858
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate (360 mg twice daily)
Study: 15577621
Drug: Interleukin-2 therapy
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 therapy (9 x 10(6) IU/day for 4-5 days)
Study: 9618617
Drug: 2 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 injections of tetanus toxoid
Study: 7999529
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation in ischaemic heart disease patients
Study: 30335073
Drug: Phenazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazepam (1 mg)
Study: 25387888
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 mg once daily for 15 days)
Study: 22014970
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 0.5% bupivacaine and i.m. 75 mg diclofenac (group BD)
Study: 19164830
Drug: Oral quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quercetin (250 mg, 4x/day; 1,000 mg/day total)
Study: 19164830
Drug: Quercetin-free supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-free supplements
Study: 19164830
Drug: Oral quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quercetin
Study: 11463999
Drug: Intensified dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified dietary counselling, ready-made liquid nutritional supplements free of charge, regular follow-ups
Study: 9923569
Drug: Mibefradil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (50 mg)
Study: 10442205
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol
Study: 3057512
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg metamizole
Study: 3057512
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metamizole
Study: 19797985
Drug: Aripiprazole 5
Normalized name: aripiprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 5 mg/day
Study: 29774635
Drug: Aripiprazole 2
Normalized name: aripiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 2 mg/day
Study: 15770435
Drug: Cholesterol-lowering medication
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering medication adherence
Study: 9032500
Drug: Dirithromycin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin, 500 mg orally once daily for five consecutive days
Study: 9032500
Drug: Erythromycin base,
Normalized name: Erythromycin Base, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin base, 1000 mg orally four times daily for seven days
Study: 29143534
Drug: Lithium-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium-based treatment
Study: 17409909
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus cisplatin (500 mg/m pemetrexed + 75 mg/m cisplatin)
Study: 1622858
Drug: Immediate surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate surgery without neoadjuvant chemotherapy
Study: 6147454
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist ranitidine (150 mg)
Study: 6147454
Drug: H1-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1-receptor antagonist terfenadine (60 mg)
Study: 27039928
Drug: Positive Airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Airway Pressure (PAP) therapy
Study: 20432816
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose isoflavone (16 mg)
Study: 15063404
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP), 750 microg, twice/day for 3 months
Study: 14555565
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP)
Study: 12564092
Drug: 0.5% trimecain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% trimecain infiltration into the thyroid capsule (n = 32)
Study: 12564092
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with saline infiltration into the thyroid capsule (n = 32)
Study: 21103664
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion for one week
Study: 16750985
Drug: Baseline bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline bronchodilator response
Study: 11081782
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive drugs (diuretics or beta-blockers)
Study: 2860336
Drug: Fenoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.2 mg/puff, 3 times 2 puffs)
Study: 2860336
Drug: Fenoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.2 mg/puff, 3 times 3 puffs)
Study: 2860336
Drug: Fenoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.2 mg/puff, 3 times 4 puffs)
Study: 24375206
Drug: LAI risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LAI risperidone 12.5 to 50 mg per injection biweekly
Study: 24375206
Drug: Psychiatrist's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatrist's choice of oral antipsychotics
Study: 9660108
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 300 mg/day
Study: 2551397
Drug: Intravenous 2-deoxy-D-glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2-deoxy-D-glucose (2DG) administration
Study: 11551575
Drug: Oral immune‐enhancing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immune‐enhancing nutritional supplement (n=25)